Cargando…

On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone

The activation of the renin–angiotensin system (RAS) is one of the unfavourable characteristics of calcium channel blocker (CCB). N type calcium channel is thought to be involved in renin gene transcription and adrenal aldosterone release. Accordingly, N/L type CCB has a possibility of less elevatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konoshita, Tadashi, Kaeriyama, Saori, Urabe, Machi, Nakaya, Takahiro, Yamada, Mika, Ichikawa, Mai, Yamamoto, Katsushi, Sato, Satsuki, Imagawa, Michiko, Fujii, Miki, Makino, Yasukazu, Zenimaru, Yasuo, Wakahara, Shigeyuki, Suzuki, Jinya, Ishizuka, Tamotsu, Nakamura, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2016
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025805/ https://www.ncbi.nlm.nih.gov/pubmed/27515419 http://dx.doi.org/10.1042/BSR20160129

Ejemplares similares

Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of aldosterone synthase
por: Ichikawa, Mai, et al.
Publicado: (2014)

Determinants of Plasma Renin Activity: Role of a Human Renin Gene Variant as a Genetic Factor
por: Konoshita, Tadashi, et al.
Publicado: (2014)

Intrathoracic Benign Goiter Imaged by (18)F-FDG-PET: A Case Report
por: Wakahara, Shigeyuki, et al.
Publicado: (2015)

A Genetic Variant in the Distal Enhancer Region of the Human Renin Gene Affects Renin Expression
por: Makino, Yasukazu, et al.
Publicado: (2015)

An association study of C9orf3, a novel component of the renin-angiotensin system, and hypertension in diabetes
por: Ichikawa, Mai, et al.
Publicado: (2020)

Hormone-sensitive lipase protects adipose triglyceride lipase-deficient mice from lethal lipotoxic cardiomyopathy
por: Yamada, Mika, et al.
Publicado: (2022)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma
por: Zenimaru, Yasuo, et al.
Publicado: (2018)

The place of ARBs in heart failure therapy: is aldosterone suppression the key?
por: Markan, Uma, et al.
Publicado: (2019)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison
por: Dabul, Samalia, et al.
Publicado: (2015)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Impact of Beta-blocker, ACE Inhibitor, and ARB therapy on thoracic aorta wall shear stress in bicuspid aortic valve patients
por: McGee, Katherine, et al.
Publicado: (2016)

MON-596 Effects of Angiotensin Type 1 Receptor Blockers (ARBs) on the Expression and Secretion of Adiponectin and Leptin in Human White Adipocytes
por: Hattori, Naoki, et al.
Publicado: (2020)

ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis
por: Gao, Yu, et al.
Publicado: (2023)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Sodium balance, circadian BP rhythm, heart rate variability, and intrarenal renin–angiotensin–aldosterone and dopaminergic systems in acute phase of ARB therapy
por: Isobe‐Sasaki, Yukako, et al.
Publicado: (2017)

The effects of ACEI/ARB, aldosterone receptor antagonists and statins on preventing recurrence of atrial fibrillation: A protocol for systematic review and network meta-analysis
por: Jia, Qiulei, et al.
Publicado: (2021)

The Effects of Different Calcium Channel Blockers on Aldosterone-Producing Adenoma Cells
por: Wang, Fen, et al.
Publicado: (2020)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents
por: Kim, Yong Hoon, et al.
Publicado: (2019)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions
por: Salim, Hamisha, et al.
Publicado: (2022)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

The histological spectrum of ARB‐induced gastritis
por: Storozuk, Tanner, et al.
Publicado: (2022)

Need to Revisit Step Therapy for ARBs
por: Ram, C. Venkata, et al.
Publicado: (2007)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis
por: Wu, Di, et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma
por: Omene, Egiroh E, et al.
Publicado: (2023)

Effects of angiotensin receptor blockers (ARBs) on clinical outcomes of patients with hypertension and COVID-19: A 7-month follow-up cohort study
por: Hadadi, Azar, et al.
Publicado: (2022)

L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB
por: Fukuda, Michio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ndfer5inp1vgumnkl8pr6bts24